Trump directs agencies to expand psychedelic research, consider therapeutic access

President Donald Trump directed federal agencies on April 17 to expand research on LSD, psilocybin, and ibogaine and consider legal therapeutic access for mental‑health patients.^[1]

The move targets a growing mental‑health crisis, as suicide rates and depression prevalence have risen sharply in recent years, and early studies suggest psychedelics may offer new treatment pathways. Trump urged agencies to speed up psychedelic research for mental‑health patients.

The White House said the initiative will be formalized through an executive order, but reports conflict on its status—Washington Post officials indicated the order is already in effect, while Detroit News noted Trump plans to sign it on Saturday.^[2] Reports differ on whether the executive order has already been signed.

The Washington Post links the initiative to Health Secretary Robert F. Kennedy Jr., a detail absent from Detroit News and Marijuana Moment coverage^[2], which focus solely on the president’s role.

If signed on Saturday, April 18, the order would direct agencies such as the National Institutes of Health and the Food and Drug Administration to allocate resources for clinical trials and streamline regulatory pathways.^[2]

Psychedelic research has gained momentum under recent bipartisan interest, with several states legalizing medical use and federal agencies funding pilot studies; Trump’s directive could accelerate that trajectory at the national level.

Critics warn that rapid expansion without robust safety protocols could expose patients to unknown risks, while supporters argue that controlled access may reduce reliance on opioids and antidepressants.

LSD, a hallucinogen first synthesized in 1938, has shown promise in treating anxiety associated with life‑threatening illnesses; psilocybin, the active compound in “magic mushrooms,” has reduced depressive symptoms in multiple trials; ibogaine, derived from an African shrub, is being studied for opioid withdrawal. Federal backing could enable larger, multi‑site studies that current funding levels cannot support.

Industry analysts estimate that a federal research program could generate billions in economic activity, from biotech startups to pharmaceutical partnerships, while also creating new clinical jobs across the country.

Lawmakers from both parties have expressed interest, with several senators announcing plans to hold hearings on psychedelic medicine, signaling that the issue may become a focal point of upcoming legislative debates.

**What this means** The directive signals a potential shift in U.S. drug policy, moving psychedelics from fringe research toward mainstream medical consideration. If the executive order is signed, federal agencies will likely receive new funding streams and regulatory guidance, accelerating clinical trials that could reshape treatment options for depression, PTSD, and addiction. However, the mixed reporting on the order’s status and the involvement of a health secretary not universally acknowledged underscore the uncertainty surrounding implementation and oversight.